Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New purpose of N-(2)-L-alanyl-L-glutamine

A glutamate dipeptide, pharmaceutical technology, applied in the field of biomedicine to achieve the effect of increasing the diameter of the femur, reducing the blood calcium concentration, and reducing the length of the femur

Inactive Publication Date: 2020-03-31
NINGBO UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above reports show that dipipeptide has a good protective effect in various cell and tissue injury models, but there is no public report on the application of dipeptide in the treatment of osteoporosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New purpose of N-(2)-L-alanyl-L-glutamine
  • New purpose of N-(2)-L-alanyl-L-glutamine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Effects of glucodipeptide on changes in femur length and diameter in rats induced by weightlessness

[0015] This embodiment provides a dosage form of dipeptide injection, which includes a dipeptide main body and a drug carrier. Wherein, the main body of dipipeptide is a composition containing one or more of dipeptide and pharmaceutically acceptable salts, esters, and solvates thereof. Wherein, the carrier includes water, physiological saline, phosphate buffer saline, bacteriostatic water, ethanol, polyalcohol and mixture thereof, as well as liposome and polymer nanoparticle. These compositions must be sterile and liquid injectables.

[0016] The experimental method is as follows:

[0017] (1) Construction of rat model of osteoporosis caused by weightlessness: SPF grade male SD rats were selected, and all rats were kept in independent cages. After the tail was cleaned, both sides of the tail of the rat were pasted with medical air-permeable adhesive tape. Then connec...

Embodiment 2

[0024] Effects of glucodipeptide on the changes of blood calcium index in rats induced by weightlessness

[0025] The experimental method is as follows:

[0026] (1) Construction of rat model of osteoporosis caused by weightlessness: same as Example 1;

[0027] (2) Rat model grouping and drug treatment: same as in Example 1.

[0028] The experimental results are as follows (Table 2): the measured ionized calcium concentration and total calcium concentration of the rats in the blank control group were 1.21±0.05 mmol / L and 2.37±0.04 mmol / L, respectively; The total calcium concentration was 1.23±0.03 mmol / L and 2.46±0.03 mmol / L, respectively; the measured ionized calcium concentration and total calcium concentration of the rats administered with dipeptide were 1.16±0.02 mmol / L and 2.33±0.03 mmol / L, respectively. Compared with the tail-suspension model group, the measured ionized calcium concentration and total calcium concentration of the rats in the dipeptide-administered grou...

Embodiment 3

[0033] Provide a kind of dipeptide tablet

[0034] The present embodiment provides a kind of dipeptide tablet, the formula is as follows: dipeptide or its salt or ester 50 g, microcrystalline cellulose 50 g, lactose 28 g, calcium hydrogen phosphate 10 g, croscarmellose sodium 5 g , 2 g of magnesium stearate, appropriate amount of purified water. Make 1000 proglu dipeptide or its salt or ester tablet.

[0035] The preparation process is as follows:

[0036] 1. Glycine dipeptide or its salt or ester is crushed through an 80-mesh sieve and set aside;

[0037] 2. Lactose passed through a 60-mesh sieve, set aside;

[0038] 3. Fully mix 1 and 2 with microcrystalline cellulose, calcium hydrogen phosphate, and croscarmellose sodium;

[0039] 4. Use water to make soft material, granulate with 20 mesh sieve, dry at 60 degrees, and granulate with 24 mesh sieve;

[0040] 5. Add magnesium stearate, mix well, and press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a new purpose of N-(2)-L-alanyl-L-glutamine. The new purpose is characterized in that the purpose is an application of the N-(2)-L-alanyl-L-glutamine or the pharmaceuticaly-acceptable salt, ester and solvate to preparation of medicines for resisting osteoporosis. Through in vivo experiment, the inventor finds that the N-(2)-L-alanyl-L-glutamine can reduce the length of thigh bones, increase the diameter of the thigh bones and reduce the indexes of blood calcium concentration and the like. The new purpose of the N-(2)-L-alanyl-L-glutamine has the advantages that medicines can be applied to treatment for resisting osteoporosis, and have treatment protective effects on primary osteoporosis, secondary osteoporosis and idiopathic osteoporosis.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a new application of dipeptide and pharmaceutically acceptable salts, esters and solvates thereof. Background technique [0002] Osteoporosis is a bone metabolic disease characterized by lower than normal bone mass per unit volume, generally manifested as decreased bone mass, degeneration of bone microstructure, increased bone fragility or susceptibility to fracture. According to the different pathogenic factors, it can be divided into two types: primary and secondary. Osteoporosis has become one of the five major diseases in the world. With the increasing incidence of osteoporosis, it seriously threatens the quality of life and life expectancy of the elderly. Osteoporosis and the fractures it causes, especially hip fractures, are one of the main causes of disability, disease and death in the elderly. At present, the number of osteoporosis patients in the world has exceeded...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/05A61P19/10
CPCA61K38/05A61P19/10
Inventor 赵玉芬任雪玲黄少华李龙王宁赵华任继伟胡静波
Owner NINGBO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com